Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free iron and copper ions are redox-active metal species that function as essential catalysts and cofactors in various biological processes, most notably melanogenesis and the generation of reactive oxygen species (ROS). Copper is a mandatory cofactor for tyrosinase, the primary enzyme responsible for converting L-tyrosine into melanin; without copper, the enzyme remains inactive (Solano, 2014). Free or labile iron contributes to skin damage by catalyzing the Fenton reaction, which converts hydrogen peroxide into highly reactive hydroxyl radicals, leading to lipid peroxidation and DNA damage (Kozlowski et al., 2014). In the context of dermatology, these ions are considered therapeutic targets for treating hyperpigmentation and photoaging. Drugs and cosmeceuticals, such as kojic acid and phytic acid, act by chelating these ions, thereby sequestering them from their biological roles in pigment production and oxidative stress (Sarkar et al., 2013). Managing the levels of these free ions is crucial for maintaining skin homeostasis and preventing conditions like melasma or post-inflammatory hyperpigmentation (Fisher et al., 2002). Therapeutic challenges include ensuring that chelators do not interfere with essential systemic metalloproteins or cause mineral deficiencies. Overall, targeting the labile metal pool provides a non-enzymatic approach to modulating skin pigmentation and protecting against UV-induced oxidative damage.
Chelation of free copper and iron ions to prevent their participation in tyrosinase activation and Fenton-mediated reactive oxygen species (ROS) generation.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free iron and copper ions (Fe and Cu ions).